Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening.
BACKGROUND: Pulmonary vasodilators in general and prostacyclin analogues in particular have improved the outcome of patients with pulmonary arterial hypertension (PAH). Endothelial dysfunction is a key feature of PAH and we previously described that circulating endothelial cell (CEC) level could be...
Main Authors: | Marilyne Levy, Damien Bonnet, Laetitia Mauge, David S Celermajer, Pascale Gaussem, David M Smadja |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3677895?pdf=render |
Similar Items
-
Correction: Circulating Endothelial Cells in Refractory Pulmonary Hypertension in Children: Markers of Treatment Efficacy and Clinical Worsening.
by: Marilyne Levy, et al.
Published: (2014-01-01) -
Correction: Circulating Endothelial Cells in Refractory Pulmonary Hypertension in Children: Markers of Treatment Efficacy and Clinical Worsening
Published: (2014-01-01) -
Potts anastomosis in children with severe pulmonary arterial hypertension and atrial septal defect
by: Alice Capel, et al.
Published: (2021-02-01) -
Monitoring of Hemodynamics With Right Heart Catheterization in Children With Pulmonary Arterial Hypertension
by: Julien Grynblat, et al.
Published: (2023-04-01) -
The latest definition and classification of pulmonary hypertension
by: Seshika Ratwatte, et al.
Published: (2024-09-01)